Drug intelligence / Profile preview

AE001

Development stage: Preclinical
Lead developer: Santen Pharmaceutical
Administration: Topical Ophthalmic

Overview

AE001 refers to at least two distinct substances depending on context. In pharmaceutical and clinical trial contexts, particularly involving Santen and ActualEyes, AE001 is being investigated as an ophthalmic treatment for Fuchs Endothelial Corneal Dystrophy (FECD)[4]. Details regarding its molecular identity, mechanism of action, or precise composition in this context are not provided in the available sources. Separately, AE001 is also listed as a research chemical from Akina, Inc., specifically methoxy poly(ethylene glycol)-FNR 552 (Mn 5,000 Da; Fluorescent Endcap), intended strictly for laboratory research and not for clinical or drug use[5].

Targets

Mechanistic target of rapamycin complex 1

Beyond the preview

Go deeper on AE001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AE001.

Explore the full profile